1 / 60

Program Goals

Program Goals. Gastric and Esophageal Cancer in the United States, 2013. Gastric Cancer Incidence: Geographic Differences. Gastric Adenocarcinoma: Heterogeneous Diseases. Gastric Cancer: Death Rates in the United States. Subcardial Gastric Cancer Incidence: Trends Among Different Age Groups.

philip-donovan
Télécharger la présentation

Program Goals

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Program Goals

  2. Gastric and Esophageal Cancer in the United States, 2013

  3. Gastric Cancer Incidence: Geographic Differences

  4. Gastric Adenocarcinoma: Heterogeneous Diseases

  5. Gastric Cancer: Death Rates in the United States

  6. Subcardial Gastric Cancer Incidence: Trends Among Different Age Groups

  7. Gastric Adenocarcinoma: Heterogeneous Diseases

  8. Esophagogastric Adenocarcinomas: Pathologic Distinctions

  9. Pathogenesis of Esophagogastric Adenocarcinomas

  10. Gastric Cancer: Molecular Subtypes With Distinct Expression Profiles

  11. Gene Signature Validated in Primary Gastric Cancers: 2 Patient Cohorts

  12. Identifying Relevant Biologic Targets to Guide Therapeutic Development

  13. Significantly Mutated Genes in Whole-exome Sequencing Studies

  14. Exome Sequencing in GEJ and Esophageal Adenocarcinoma

  15. Candidate Biologic Pathways in Gastric Cancer

  16. Gastric Cancer: Single-Agent Chemotherapy

  17. Chemotherapy Regimens for Metastatic Esophagogastric Cancer

  18. HER/ErbB Family in Gastric Cancer

  19. ToGA: Phase 3 Trial of Trastuzumab in First-line Gastric/GEJ Cancer

  20. ToGA Primary End Point: OS

  21. ToGA Efficacy: OS by Subgroup Analysis

  22. HER2- Expression Frequency by Histologic Subtype

  23. T-DM1 Structure

  24. HER/ErbB Targeting in Gastric Cancer

  25. Rilotumumab in First-line Gastric/GEJ Cancer: Phase 2 Trial

  26. Rilotumumab Efficacy in ITT Population

  27. Rilotumumab Efficacy in MET-High Population

  28. Role of VEGF Pathway in Tumor Growth

  29. VEGF Expression Associated With Worse Survival in Gastric Cancer

  30. AVAGAST: Bevacizumab in First-line Gastric/GEJ Cancer - Phase 3 Trial

  31. AVAGAST Primary End Point: OS

  32. Role of VEGF Pathway in Tumor Growth

  33. Neovascularization and VEGFR2 Expression from Barrett’s to Esophageal Adenocarcinoma

  34. Anti-VEGFR2 MAb in a Gastric Cancer Animal Model

  35. REGARD: Ramucirumab Monotherapy in Second-line Gastric/GEJ Cancer, Phase 3 Trial

  36. REGARD: Efficacy Results

  37. RAINBOW: Ramucirumab in Second-line Gastric/GEJ Cancer, Phase 3 Trial

  38. Summary and Conclusions

  39. Summary and Conclusions (cont)

  40. Abbreviations

  41. Abbreviations (cont)

  42. Abbreviations (cont)

More Related